Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma (ASMATHERM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01777360|
Recruitment Status : Unknown
Verified November 2017 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Active, not recruiting
First Posted : January 28, 2013
Last Update Posted : November 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Device: ALAIR, radiofrequency catheter for bronchial THERMOPLASTY||Phase 3|
Bicentric prospective study, evaluating bronchial THERMOPLASTY in patients with severe uncontrolled asthma and significant bronchial smooth muscle mass. Primary Objective is to determine patients who would be the best candidates for bronchial THERMOPLASTY which should improve control of the asthma, reduce day-to-day symptoms and severe exacerbations, and improve respiratory function. Primary Endpoint will be the reduction in smooth muscle surface area, objectified on bronchial biopsies before and after THERMOPLASTY in patients presenting severe asthma and secondary criteria are:
- number of severe exacerbations (with oral corticosteroids, emergency room visits, hospitalizations)
- time until the first exacerbation
- respiratory function
- control of the asthma (ACQ - Asthma Control Questionnaire)
- quality of life (AQLQ - Asthma Quality of Life Questionnaire)
- fraction of exhaled nitric oxide (FENO)
- measurement of the thickness of the bronchial wall using tomodensitometry (scan). The inclusion of period of 28 months is limited to a maximum of 80 subjects. The actual number will be determined using the two-stage stop method. An intermediate analysis will be carried out following the evaluation and statistical analysis of the 40 patients.
- If the primary endpoint p-value is <0.0294, success will be declared and the inclusions will cease.
- If the p-value is >0.0294, additional patients will be recruited up to a total of 80 patients included and assessed. At inclusion, sociodemographic data will be collected, number of exacerbations per year, date of fibroscopy, data on asthma control (ACQ), data on quality of life (AQLQ), respiratory function (EFR), fraction of exhaled nitric oxide (FENO), thickness of the bronchial wall evaluated using scanner and surface area of smooth muscle in the bronchial sub-mucous layer will be evaluated. At 3 months post-THERMOPLASTY, same data will be collected. One year after THERMOPLASTY, number of exacerbations, data on asthma control (ACQ),and quality of life (AQLQ), respiratory function (EFR), fraction of exhaled nitric oxide (FENO), thickness of the bronchial wall and possible complications will be collected.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma|
|Actual Study Start Date :||December 2012|
|Actual Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||September 2018|
ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
Device: ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
radiofrequency catheter for bronchial THERMOPLASTY
- smooth muscle surface area [ Time Frame: 3 month after THERMOPLASTY ]Reduction in smooth muscle surface area, objectified on bronchial biopsies before and after THERMOPLASTY in patients presenting severe asthma.
- respiratory function [ Time Frame: 12 month after thermoplasty ]number of severe exacerbations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01777360
|Paris, France, 75018|
|Principal Investigator:||Aubier Michel||Assistance Publique - Hôpitaux de Paris|